Effect of the rho-kinase inhibitor ripasudil in needling with mitomycin C for the failure of filtering bleb after trabeculectomy: a cross-sectional study.
Glaucoma
Mitomycin C
Needling
Rho-associated protein kinase inhibitor
Ripasudil
Trabeculectomy
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
14 Nov 2022
14 Nov 2022
Historique:
received:
05
08
2022
accepted:
09
11
2022
entrez:
15
11
2022
pubmed:
16
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Rho-kinase inhibitors can inhibit fibrosis after glaucoma surgery. This study aimed to evaluate the effect of rho-kinase inhibitor after needling procedure with mitomycin C for the failure of filtering bleb with trabeculectomy. This retrospective single-center study examined the effects of rho-kinase inhibitor after the needling procedure. We included 27 eyes of 27 patients with glaucoma who underwent needling procedure using mitomycin C and were subsequently treated with ripasudil-a rho-associated protein kinase inhibitor (ripasudil group)-or without ripasudil (control group). The ripasudil and control groups were compared in terms of intraocular pressure (IOP) and the number of antiglaucoma medications. Success at 12 months after the needling procedure was defined as a > 20% decrease in IOP from the preoperative period without surgical reintervention. At 12 months after the needling procedure, the mean IOP decreased from 16.9 ± 4.5 to 12.6 ± 1.1 mmHg in the control group and from 16.0 ± 5.3 to 12.2 ± 1.2 mmHg in the ripasudil group (p = 0.77). The 12-month success rates were 60.00% and 56.25% in the control and ripasudil groups (p = 0.98), respectively. In the preoperative period, the numbers of antiglaucoma drugs were 0.27 ± 0.46 and 0.92 ± 0.91 in the control and ripasudil groups (p = 0.022), respectively, and at 12 months after the needling procedure, they were 1.07 ± 1.44 and 0.73 ± 1.10 (p = 0.52), respectively. Treatment with ripasudil (a rho-associated protein kinase inhibitor) after the needling procedure with mitomycin C did not show better results than treatment with the mitomycin C needling procedure alone at 12 months after the procedure.
Sections du résumé
BACKGROUND
BACKGROUND
Rho-kinase inhibitors can inhibit fibrosis after glaucoma surgery. This study aimed to evaluate the effect of rho-kinase inhibitor after needling procedure with mitomycin C for the failure of filtering bleb with trabeculectomy.
METHODS
METHODS
This retrospective single-center study examined the effects of rho-kinase inhibitor after the needling procedure. We included 27 eyes of 27 patients with glaucoma who underwent needling procedure using mitomycin C and were subsequently treated with ripasudil-a rho-associated protein kinase inhibitor (ripasudil group)-or without ripasudil (control group). The ripasudil and control groups were compared in terms of intraocular pressure (IOP) and the number of antiglaucoma medications. Success at 12 months after the needling procedure was defined as a > 20% decrease in IOP from the preoperative period without surgical reintervention.
RESULTS
RESULTS
At 12 months after the needling procedure, the mean IOP decreased from 16.9 ± 4.5 to 12.6 ± 1.1 mmHg in the control group and from 16.0 ± 5.3 to 12.2 ± 1.2 mmHg in the ripasudil group (p = 0.77). The 12-month success rates were 60.00% and 56.25% in the control and ripasudil groups (p = 0.98), respectively. In the preoperative period, the numbers of antiglaucoma drugs were 0.27 ± 0.46 and 0.92 ± 0.91 in the control and ripasudil groups (p = 0.022), respectively, and at 12 months after the needling procedure, they were 1.07 ± 1.44 and 0.73 ± 1.10 (p = 0.52), respectively.
CONCLUSIONS
CONCLUSIONS
Treatment with ripasudil (a rho-associated protein kinase inhibitor) after the needling procedure with mitomycin C did not show better results than treatment with the mitomycin C needling procedure alone at 12 months after the procedure.
Identifiants
pubmed: 36376831
doi: 10.1186/s12886-022-02680-9
pii: 10.1186/s12886-022-02680-9
pmc: PMC9664808
doi:
Substances chimiques
K-115
0
Mitomycin
50SG953SK6
Protein Kinase Inhibitors
0
rho-Associated Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
433Informations de copyright
© 2022. The Author(s).
Références
Cell Biochem Funct. 2019 Mar;37(2):113-124
pubmed: 30773659
J Glaucoma. 2001 Jun;10(3):237-49
pubmed: 11442190
Ophthalmology. 1996 Nov;103(11):1946-55
pubmed: 8942894
J Ophthalmol. 2020 Nov 30;2020:4310258
pubmed: 33335782
Invest Ophthalmol Vis Sci. 1985 Feb;26(2):170-5
pubmed: 4038695
Surv Ophthalmol. 2000 Jul-Aug;45(1):49-68
pubmed: 10946081
Br J Ophthalmol. 1983 Oct;67(10):661-3
pubmed: 6615752
Arch Ophthalmol. 1977 Sep;95(9):1612-5
pubmed: 901270
Sci Rep. 2016 Jan 19;6:19640
pubmed: 26782355
Arch Ophthalmol. 1994 Nov;112(11):1437-45
pubmed: 7980133
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57
pubmed: 18055804
Ophthalmology. 2002 Apr;109(4):781-5
pubmed: 11927440
J Glaucoma. 2006 Apr;15(2):98-102
pubmed: 16633221
Am J Ophthalmol. 1990 Sep 15;110(3):254-9
pubmed: 2396649
Arch Ophthalmol. 1981 Apr;99(4):635-49
pubmed: 6164357
Arthritis Rheum. 2008 Aug;58(8):2553-64
pubmed: 18668558
Exp Eye Res. 2016 Aug;149:107-115
pubmed: 27394186
J Glaucoma. 2008 Oct-Nov;17(7):594-600
pubmed: 18854740
Jpn J Ophthalmol. 2018 Mar;62(2):109-126
pubmed: 29445943
Arch Ophthalmol. 1994 Nov;112(11):1446-54
pubmed: 7980134
Am J Ophthalmol. 2013 Oct;156(4):731-6
pubmed: 23831221
PLoS One. 2017 Jul 20;12(7):e0181550
pubmed: 28727804
Acta Ophthalmol. 2015 Jun;93(4):e254-60
pubmed: 25487877
J Glaucoma. 2005 Feb;14(1):52-6
pubmed: 15650605
Surv Ophthalmol. 1987 Nov-Dec;32(3):149-70
pubmed: 3328315
Am J Ophthalmol. 1996 Aug;122(2):195-204
pubmed: 8694087
Am J Ophthalmol. 1968 Oct;66(4):673-9
pubmed: 4891876
Adv Ther. 2019 Feb;36(2):333-343
pubmed: 30610614
Surv Ophthalmol. 2003 May-Jun;48(3):314-46
pubmed: 12745005
Ophthalmic Surg Lasers Imaging. 2012 Jan-Feb;43(1):32-8
pubmed: 22251843
BMC Ophthalmol. 2015 Dec 17;15 Suppl 1:157
pubmed: 26818010
Am J Ophthalmol. 2001 Dec;132(6):875-80
pubmed: 11730652
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1975 Mar-Apr;79(2):OP342-8
pubmed: 1145957